ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Lonza, Genentech in biopharma deal

November 13, 2006 | APPEARED IN VOLUME 84, ISSUE 46

Contract manufacturer Lonza has agreed to pay $150 million for Genentech's biologics manufacturing facility in Porrino, Spain. The 40,000 L of cell culture capacity at the Porrino site is currently dedicated to the production of Genentech's cancer drug Avastin. Lonza will continue to make Avastin for Genentech there under a short-term supply agreement. Lonza has also agreed to add an 80,000-L mammalian cell culture facility to its site in Singapore, where an 80,000-L plant is already under construction. Genentech has an exclusive option to acquire one of Lonza's Singapore plants anytime between 2007 and 2012 for $290 million plus $70 million in performance milestones. The deal includes a separate supply agreement for Avastin and other Genentech oncology products to be made in Singapore. Lonza already manufactures Rituxan, a Genentech oncology treatment, at its site in Portsmouth, N.H.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment